Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p = 0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer. © 2008 Elsevier Ireland Ltd. All rights reserved.
CITATION STYLE
Karasawa, K., Sunamura, M., Okamoto, A., Nemoto, K., Matsuno, S., Nishimura, Y., & Shibamoto, Y. (2008). Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study. Radiotherapy and Oncology, 87(3), 326–330. https://doi.org/10.1016/j.radonc.2008.02.007
Mendeley helps you to discover research relevant for your work.